Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy.
Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an a...